Advertisement Mymetics to manufacture Imugene's Virosome based HER-Vaxx cancer immunotherapy - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Mymetics to manufacture Imugene’s Virosome based HER-Vaxx cancer immunotherapy

Swiss biotechnology firm Mymetics has signed an exclusive agreement with Imugene, an Australian biopharmaceutical company, to manufacture and develop its cancer immunotherapy HER-Vaxx.

Imugene’ cancer immunotherapy vaccine candidate HER-Vaxx is scheduled to enter into a Phase I/II clinical trial in 2015.

Under the deal, Mymetics will use its strong experience and specialist know-how in virosome based vaccines and integrating antigens in viral membranes to manufacture HER-Vaxx.

Mymetics CEO Ronald Kempers said the company is happy that Imugene has decided to engage with them for the manufacturing of their proprietary HER-Vaxx immunotherapy.

"It further confirms and recognizes Mymetics as a global leader and niche player in the development and formulation of virosomes and integration of membrane proteins and peptides for immunotherapy and vaccine candidates," Kempers said.

Imugene executive director Nick Ede said: "Mymetics uses the same vaccine delivery platform for infectious diseases that we are using for our immuno-oncology program and together both companies will work to exploit the potential value of influenza-based virosomes."

Mymetics develops next-generation preventative vaccines for infectious diseases, and its core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins, in combination with rationally designed antigens.